Article Type : Case Report
Authors : Hayashi K, Yasuoka T, Bando H, Miki K, Nakagawa M, Zushi T, Suzuki C, Shibata R, Takata T and Sato M
Keywords : Multiple daily insulin injection (MDI); Xultophy; Type 2 Diabetes Mellitus (T2DM); Bio-psycho-social; Glucagon like peptide-1 receptor agonist (GLP-1RA)
The case was 79-year-old female with type 2 diabetes
mellitus (T2DM) and other medical problems who has been treated on insulin for
Multiple Daily Injections (MDI). She has recently developed cough and was
diagnosed as slight bronchopneumonia, followed by the admission to the hospital
with intensive treatment. Simultaneously, she could not control her usual daily
life, and then her diabetic therapy was changed to Xultophy. It is the combined
agent of liraglutide and insulin degludec that can be injected once a day. In
this article, the clinical progress and some discussion from various points of
view would be described.
The prevalence of diabetes has been increasing
in the world. It is usually associated with non-communicable diseases (NCDs),
such as obesity, metabolic syndrome, nonalcoholic fatty liver disease (NAFLD),
and so on (Met-S) [1]. For the treatment for these diseases, adequate
nutritional therapy and weight control would be required. As regard to Type 2
diabetes mellitus (T2DM), it is important to reduce several risks of
macroangiopathy and microangiopathy [2]. In other words, optimal control of
daily profile of blood glucose, adequate treatment for diabetes using oral
hypoglycemic agents (OHAs) and/or injectable agents are important, as well as
patient-oriented medical goal [3]. Concerning the therapy for T2DM, the basic
principle is adequate nutritional treatment. For previous decade, the usual
diet therapy was calorie restriction (CR), in which fat food was limited for
reducing total calorie. After various nutritional practice and research, low
carbohydrate diet (LCD) was introduced for effective way of managing T2DM [4].
Clinical efficacy of LCD has been proposed with several studies for years in
European and North American regions [5,6]. On the other hand, authors and
collaborators have started LCD in Japan and developed LCD therapy in Japan
until now [7]. We established Japan LCD Promotion Association (JLCDPA), and
continued development of LCD medically and socially through many opportunities
for workshops, seminars, medical societies and books [8]. For practical use,
three recommended type of LCD have been informed broadly. They are super LCD,
standard LCD and petite LCD with carbohydrate ratio as 12%, 26%, and 40%,
respectively [9]. Moreover, clinical research has been continued with several
medical themes, such as daily profile of blood glucose, insulinogenic index
(IGI), Morbus (M) value, meal tolerance test (MTT), continuous glucose
monitoring (CGM) and clinical application of Xultophy [10]. In the light of
pharmacological agents, several kinds of glucagon like peptide-1 receptor
agonists (GLP-1RAs) have been used in the diabetic therapy [11]. For example,
there are liraglutide, dulaglutide, lixisenatide, exenatide, and others [12].
Among some research for GLP-1RAs, Network Meta-Analysis (NMA) showed the useful
evaluation clinically for diabetic control and also some outcomes for
atherosclerotic cardiovascular disease (ASCVD) [13]. As a result, the effect of
cardiometabolic benefits was found by using GLP-1RA regimens. In the group of
GLP-1RA agents, liraglutide has been effective and rather widely applied to
diabetic patients. Related to this prevalence, Xultophy has been made and used
for actual practice as the combination of liraglutide and insulin degludec
[14]. When compared with either one agent each, this combined agent revealed
better effect [15]. GLP-1RA brings the improved findings for reducing fasting
plasma glucose and postprandial glucose [16]. Furthermore, basal insulin brings
the improved result for decreasing fasting plasma glucose, and this combined
agent with fixed ratio can lead improved general diabetic control by injection
once per day. In addition, Xultophy has the efficacy to maintain
cardioprotective activity by improving the function of beta cell in the
pancreas [17]. Diabetic practice and research for years concerning CGM, MMT,
Xultophy and others. Among our experience, a female elderly case receiving the
treatment of Xultophy was found. She showed the effect of Xultophy, as well as
the meaningful perspective from bio-psycho-social points of view. Xultophy may
be useful in the light of patient-oriented medicine which is the recommended
goal for medical practice. In this article, the clinical course and some
discussion will be described.
Past
history
When she was 59 years
old, she was pointed out to have type 2 diabetes mellitus (T2DM). After that,
she had several diseases until 69 years old, including hypertension, atrial
fibrillation (Af), hyperlipidemia, cerebral infarction in the left thalamus to
slight degree and gastro esophageal reflux disease (GERD). Successively, she
had developed arthralgia of large joints, and was diagnosed as rheumatoid
arthritis (RA) at the age of 70 years old. When she was around 75 years old,
she complained of left low back pain, associated with the diagnosis of left
ureteral stone, bilateral renal stone and osteoporosis. Her arthralgia has been
controlled by small doses of prednisolone 5 mg/day for the treatment of RA
during 70 to 79 years old. Regarding the medical history from Feb 2017 to Nov
2020, she received a simple operation of abdominal wall scar hernia. Endoscopic
examination was performed once a year for upper gastrointestinal tract, which
showed reflux esophagitis (GERD grade D). The results on Feb, 2021 included i)
GERD grade D (reflux esophagitis), ii) hiatal hernia slippery type, severe,
iii) chronic active gastritis (atrophic gastritis) C-III, yellow tumor in the
stomach, and iv) subduodenal mucosa, which are not particularly problematic.
Present
history
She has been diabetic
for 20 years and taking insulin for 1 year. In late Dec 2020, her lower body
became weakened, which caused her to fall down a few times. This episode
brought her back pain and inability to get up. She was transferred to Tokushima
Red Cross Hospital (TRCH) and was proved to show low blood glucose as 55 mg/dL.
On her spine XP, compression fractures were found in three locations, Th12, L4,
and L5. Head CT shows periventricular hyperlucency and many small previoius
lacuna infarcts in the basal ganglia. Chest XP showed mild bronchopneumonia in
the upper right lobe. No obvious fever was observed, SpO2 was in the
normal range, and Ceftriaxone Sodium Hydrate (CTRX) 1g was administered every
12 hours for some days. Gradually, her general condition improved, and she was
transferred to Hayashi hospital. In the past few months, she has been difficult
to properly manage insulin injections by MDI, because she could not inject
properly predetermined units of insulin.
Current
insulin treatment
She has a long history
of diabetes and has recently received insulin treatment. After hospitalization
in late Dec 2020, she had Multiple Daily Injections (MDI) to control blood
glucose [18]. The long-acting insulin used was administered with glargine once
before bedtime, and the fast-acting insulin was administered with insulin human
three times daily before meals. As to insulin units, insulin human was given
three times a day by the sliding scale procedure at pre-prandial time [19]. The
method was as follows. i) 61-80 mg/dL: glucose 10g per os, ii) 81-200 mg/dL
human 0 unit, iii) 201-250 mg/dL: 2 units, iv) 251-300 mg/dL: 4 units, v)
301-350 mg/dL: 6 units, vi) 351- mg/dL <: 8 units. In fact, the diurnal
variation in blood glucose was 107-215-217-274 mg/dL, which was poorly
controlled.
Physical
examination
Consciousness is alert,
and speech is ordinary. Vitals showed pulse rate 67/min, and blood pressure
130/67 mmHg. Her physique showed 148 cm in height, 68kg in weight, 31 kg/m2
in body mass index (BMI) with ideal body weight (IBW) as 48.2kg. Physicals
showed that lung vesicular, heart no significant murmurs, abdomen soft, flat,
no tenderness, bowel sound audible. Neurological findings showed unremarkable.
Several
examinations
The results of several examinations on admission to Hayashi Hospital were as follows. Hb 10.2 g/dL, RBC 422 x 106 /?L, Ht 32.5%, MCV 77 fL (80-98), MCH 24.2 pg (27-34), MCHC 31.4 g/dL (31-36), WBC 8800 /?L, Plt 35.2 x 104 /?L, BUN 27 mg/dL, Cr 1.41 mg/dL, uric acid 6.6 mg/dL, eGFR 28 mL/min/1.73m2, TG 75 mg/dL, HDL-C 51 mg/dL, LDL-C 87 mg/dL, T-C 153 mg/dL, TP 5.9 g/dL, Alb 3.3 g/dL, A/G ratio 1.27, Alb 55.9%, ?1-glb 4.0%, ?2-glb 11.5%, ?-glb 11.8%, ?-glb 16.8%, AST 13 U/L, ALT 7 U/L, ?-GT 13 U/L, ALP 199 U/L, LDH 229 U/L (100-340), LAP 41 U/L (30-70), ChE 198 U/L (213-501), T-Bil 0.5 mg/dL, CK 69 U/L (41-153), amylase 48 U/L (35-125), CRP 3.15 mg/dL, HBs Ag negative, TSH 5.9 ?IU/mL (0.35-4.94), free T4 1.16 ng/dL (0.7-1.48). Concerning diabetes, HbA1c 8.0%, fasting blood glucose 116 mg/dL, Urinary C-peptide 24.4 ?g/day (23-155), urinary albumin 199 mg/day (2-20). Other examinations except blood tests were as follows: Hasegawa Dementia Scale-Revised (HDS-R) 20 points (22-30). Mini-Mental State Examination (MMSE) 20 points (20/30). Chest X-P showed mild pulmonary congestion with CTR 55%. Electrocardiogram (ECG) showed atrial fibrillation (Af). Several tests included that no retinopathy in fundus, nerve conduction velocity (NCV) within normal limits, the coefficients of variation of RR intervals (CV-RR) 1.95%, abdominal echo showed chronic liver disease and hemangioma in the segment 5 (10 x 7 x 10mm), ankle brachial index (ABI) 1.13/1.19. cardio-ankle vascular index (CAVI) 10.0/10.0.
Table 1: Changes in daily profile of blood glucose for MDI and Xultophy.
Date |
Daily
profile of Blood Glucose |
Treatment |
|||||
morning |
noon |
evening |
night |
Xultophy |
Human |
Glargine |
|
(mg/dL) |
(mg/dL) |
(mg/dL) |
(mg/dL) |
(doses) |
(unit) |
(unit) |
|
-7 |
107 |
186 |
304 |
228 |
0-0-6-2 |
4 |
|
-6 |
99 |
217 |
264 |
202 |
0-2-4-2 |
4 |
|
-5 |
100 |
280 |
206 |
276 |
0-4-2-4 |
4 |
|
-4 |
96 |
309 |
119 |
257 |
0-6-0-4 |
4 |
|
-3 |
99 |
241 |
188 |
236 |
0-2-0-2 |
4 |
|
-2 |
109 |
256 |
181 |
236 |
0-4-0-2 |
4 |
|
-1 |
98 |
276 |
157 |
273 |
0-4-0-4 |
4 |
|
1 |
92 |
230 |
5 |
||||
2 |
96 |
270 |
5 |
||||
3 |
100 |
282 |
6 |
||||
4 |
111 |
232 |
6 |
||||
5 |
92 |
225 |
6 |
||||
6 |
87 |
233 |
7 |
||||
7 |
87 |
300 |
7 |
||||
8 |
104 |
241 |
7 |
||||
9 |
93 |
295 |
8 |
||||
10 |
88 |
190 |
8 |
||||
11 |
95 |
210 |
8 |
||||
12 |
75 |
174 |
8 |
||||
13 |
79 |
226 |
8 |
||||
14 |
86 |
230 |
8 |
||||
15 |
69 |
discharge |
8 |
Problems
and prescription
From mentioned above, current medical problems are
summarized in the following. #1 T2DM: MDI treatment, #2 bronchopneumonia:
antibiotics given, #3 compression fractures of spine: (Th12, L4, L5). #4 RA:
prednisolone 5mg/day administration, #5 Af, #6 GERD: grade D (reflux
esophagitis). The prescriptions concerning medical problems include amlodipine
besilate (Amlodine ®) 5mg 1T, prednisolone (Predonin ®) 5mg 1T, edoxaban
tosilate hydrate (Lixiana ®) 30mg 1T, celecoxib (Celecox ®) 100mg 4T /day,
rebamipide (Mucosta ®) 100mg 3T /day, suvorexant (Belsomra ®) 10mg 1T vds. As
an evaluation of nutritional status, mild undernutrition is observed from the
decreased data in TP, Alb, and A / G ratios, and anemia is observed from a low
Hb value. Meals during hospitalization include 1600 kcal / day, protein 59 g /
day, and water 1362 ml / day. In addition, there are moderate nutritional
risks, mild undernutrition, obesity and anemia. The meal content was set to
1600 kcal, protein 59 g, water 1362 ml, and salt 6.2 g or less per day.
Clinical
course
It was difficult for
the patient to perform MDI completely due to the sliding scale three times a
day. Several reasons were present, such as i) existing rather dementia of the
patient, ii) the cooperation of the family is difficult during the daytime, and
others. Consequently, the treatment for glucose variability was decided to
start injection of Xultophy, which can be injected once a day. It started on January
25th at 5 doses of Xultophy. The changes of the glucose daily profile during
the clinical course was summarized in Table
1. As a result, the application of Xultophy seemed to bring satisfactory
glucose control. The successful results have encouraged the patient and also
the family to continue diabetic therapy with Xultophy associated with adequate
regular lifestyle. When she was discharged from the hospital, the infection was
completely cured and diabetes control was good. The value of HbA1c during Dec
2020 to Feb 2021 was 8.0%, 7.1% and 7.2%, respectively. The prescription at
discharge was i) ipragliflozin L-proline (Sugra ®) 50 mg / day, ii) azilsartan
(Azilva ®) 20 mg 1T, iii) suvorexant (Belsomra ®) 10 mg 1T 1 x vds, iv)
vonoprazan fumarate (Takecab ®) 10 mg 1T (Table 1).
Historically, diabetic treatment has been
developed including oral hypoglycemic agents (OHAs) and some kinds of
injections such as insulin and GLP-1RA. For better control of glucose
variability, insulin treatment was recommended as the regimen of basal-bolus
injection [20]. For further natural changes in glucose and insulin, multiple
daily injection (MDI) was recommended for standard method of controlling blood
glucose as possible. It is indeed that it is ideal situation, but continuous
3-4 times daily injections seem to be taken too much efforts for the diabetic
patient and family. Recent topic includes clinical introduction of Xultophy to
patients with T2DM, which seems to be effective, convenient and useful way of
regimen [14]. Some consecutive studies of clinical effect of Xultophy are
observed, that is the European Xultophy Treatment Retrospective Audit (EXTRA)
study. There was a real-word evidence (RWE) study (EXTRA) from the European
diabetes centers [21]. As a result, significant decrease of HbA1c level (0.7%)
and weight reduction (2.4 kg) for 6 months were found in the cases who have
changed the treatment from MDI to Xultophy. EXTRA study has included more than
600 cases in 5 countries. The results showed that initiation treatment brought
0.9% HbA1c decrease for 6 months (p<0.001) [22]. From these data, Xultophy
was estimated to reveal effective and useful injectable agent, as well as
convenient regular lifestyle of the patient and the family. This case was
firstly admitted to the diabetes department in a large hospital and had been
treated with MDI. When her clinical situation became stable, she was
transferred to our hospital. The MDI method is certainly ideal for glycemic
control, but it is not easy to continue in her daily life [18]. During hospitalization,
medical staffs can help management of MDI treatment with sliding scale method.
However, when the patient is at home, it is not easy to continue it for the
patient and family. In this case, the treatment was changed from MDI to
Xultophy once a day. The first amount were 5 doses. The standard method of
administration of Xultophy is to start with 16 doses in the patients with
already treated on insulin [14]. When the patient is naïve for using insulin,
the recommended doses would be 10 doses. However, there seem to be different
situation between Western countries and Eastern countries. Authors have some
clinical experiences to control glucose variability by Xultophy with small
doses [23]. With reference to our former cases, this case was started to be provided
Xultophy from small doses. After that, we increased the doses of Xultophy up to
8 doses, where the profile of blood glucose became rather stable. The case is
elderly patient associated with several medical problems, then we did not
intend to maintain the strict control of diabetes. Another factor would be
present. The case has been taking prednisolone for the anti-inflammatory effect
against RA. Based on her medical history, she was diagnosed as T2DM 20 years
ago, and was diagnosed as RA 9 years ago. Then, she started to be taken
prednisolone. From this history, it is suggested that the elevated blood
glucose may be from several causes, including i) the presence of primary T2DM,
ii) inflammatory influence of RA and iii) secondary influence of steroid
administration [24]. Current diurnal fluctuations in blood glucose show lower
in the morning and higher in the evening. If the time period of providing
prednisolone changes, the daily profile of blood glucose may change [23]. When
a diabetic patient is taking steroids for RA, it is difficult to evaluate
detail glucose variability because hyperglycemia is influenced from both of
diabetes and steroids. From Pubmed database, complete literature search was
conducted for all relative reports [25]. The combined keywords included DM,
insulin, hyperglycemia, glucocorticoids therapy, glucose-lowering drugs,
SGLT-2i, GLP-1RA, DPP-4i. Related to these factors, further accumulation of
data would be expected for future investigation and analysis. This case seemed
to have characteristic glycemic variability. She was satisfactory pre-prandial
glucose level in the early morning. However, post-prandial glucose level in the
afternoon was rather higher. For improving this tendency, provided dose in
Xultophy was increased, but rather hyperglycemia was persisted. Possible reason
may be included from the medical history and laboratory data. She has chronic
inflammatory situation due to RA, and decreased values of TP, albumin, A/G
ratio. From these, possible existence of liver dysfunction may bring the
influence of converting glucose into glycogen associated with reduced restoring
function [26]. Consequently, overloaded glucose may flow into blood vessels,
which causes acute glucose elevation after meal period [27]. If the patient has
impaired liver function, gluconeogenesis in the liver would be decreased.
Consequently, glucose level would be lower in the early morning [28]. Regarding
the background of the case, detail situation would be evaluated from three
aspects which are bio-psycho-social axes [29]. The first is bio-axis. For
stable control of blood glucose, a series of treatments called blood glucose
measurement-sliding scale method-MDI is ideal. However, it seems to be not easy
as a matter of fact. From the clinical effect of Xultophy, a satisfactory level
of therapeutic efficacy is expected. The second is psycho-axis [30]. The
patients themselves are elderly and managing the MDI method can be a hassle. In
addition, there is a borderline condition for dementia and/or mild cognitive
impairment (MCI). Based on the above, the application of Xultophy is
recommended. The third is social-axis. It is preferable that the patient's
family can contribute to the coverage of the treatment to some extent. For this
point, it is difficult for the family to cooperate with the MDI method. On the
other hand, the injection of Xultophy once a day has the advantage of possible
assistance. Considering the mentioned axes above, Xultophy is considered to be
preferable news for elderly diabetic patients. Regarding the course of HbA1c in
this case, it was stable at 7.1-7.2% in Feb-Mar 2021. There are some
limitations in this report. We report here one case with satisfactory results
of Xultophy administration from various points of view. Further accumulation of
cases would be required for future research. Medical staffs have to consider
the background of the patient such as family situation. Xultophy is reported to
have wide beneficial efficacy and further detail investigation will be expected
[31]. In summary, a patient with T2DM was treated with Xultophy and several
perspectives were discussed. For older diabetic patients, Xultophy would be
probably recommended for better control of glucose variability and for improved
daily life form bio-psycho-social points of view. This report becomes hopefully
a reference for diabetic clinic and research in the future.
The authors declare no conflict of interest.
There was no funding received for this paper.